The company will advance zalsupindole into Phase II development and finance a broader pipeline expansion. The drug is being designed to treat psychiatric and psychological disorders.
In animal models, single doses of the therapy increased prefrontal cortex dendritic spine density and generated lasting antidepressant activity.
Delix plans to advance this asset toward a Phase II placebo-controlled trial in early 2027.
The proceeds will also fund the expansion of its neurodegeneration programmes, which have previously demonstrated preclinical efficacy signals.
Johnson & Johnson’ Innovation’s venture capital arm JJDC and SV Health Investors’ Dementia Discovery Fund co-led the financing round.
Additional participants included Adage Capital Management, Artis Ventures, Bail Capital, Dolby Family Ventures, Hamilton Square Partners Management, OMX Ventures, RA Capital, UC Investments, Vestal Point Capital, and YK Bioventures.
Following the investment, SV Health Investors partner and JJDC representative Christian Jung joined the Delix board of directors.
Delix Therapeutics CEO Mark Rus said: “We are proud to welcome our new investors alongside the continued support of our existing shareholders as Delix enters its next stage of growth. The strength and validation of this syndicate reflects the growing conviction and data for neuroplastogens as an important new therapeutic class.
“This capital enables us to take zalsupindole through Phase II Proof of Concept, advance a broader pipeline of differentiated medicines, and build Delix for the long term.
“We are particularly excited to partner with investor teammates who understand what it takes to translate breakthrough neuroscience into medicines that can reach patients at scale. Delix is more well positioned than ever to define the next chapter of true neuroplastogen medicine.”
Delix is also advancing a pipeline of neuroplastogens targeting psychiatric, neurological, and neurodegenerative diseases.
The Series C financing is expected to help the company move additional candidates into clinical development while broadening its reach into new indications.